RecruitingNCT06644625

CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study


Sponsor

Wake Forest University Health Sciences

Enrollment

1,665 participants

Start Date

Mar 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.


Eligibility

Min Age: 30 Years

Plain Language Summary

Simplified for easier understanding

The CHAAMP study is a free screening program to detect early signs of multiple myeloma or related blood protein disorders (called monoclonal gammopathy) in communities at higher risk, particularly Black and African American individuals and people with a family history of blood cancers. **You may be eligible if...** - You are 30 years old or older - You identify as Black and/or African American, OR - You have a parent, sibling, or child who has been diagnosed with a plasma cell disorder (such as multiple myeloma, MGUS, or Waldenström's macroglobulinemia) - You live in or near Charlotte, NC - You are willing and able to provide informed consent **You may NOT be eligible if...** - You have already been diagnosed with MGUS, smoldering myeloma, multiple myeloma, AL amyloidosis, or a related plasma cell disorder - You are not located in the Charlotte, NC area Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBlood draw for the laboratory assessment

Screening blood sample collection to test for MGUS


Locations(1)

Atrium Health Levine Cancer

Charlotte, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06644625


Related Trials